Veradermics (MANE) affiliate plans NYSE sale via BofA Securities

Rhea-AI Filing Summary

Veradermics, Inc. (MANE) is the issuer of common stock that Averill Master Fund, Ltd., an affiliate, has filed to sell under Rule 144. The notice covers up to 690,601 shares of common stock, to be sold through BofA Securities, Inc. as broker on the NYSE. The shares were acquired from Veradermics upon conversion of Series B Preferred Stock, which was obtained on November 25, 2024 and converted on February 5, 2026. No other Rule 144 sales by this seller are listed for the prior three months.

Key Figures

Shares to be sold: 690,601 shares Conversion date: 02/05/2026 Preferred stock acquisition date: 11/25/2024 +1 more

4 metrics

Shares to be sold 690,601 shares Common stock of Veradermics, Inc. covered by this Rule 144 notice

Conversion date 02/05/2026 Date Series B Preferred Stock was converted into common stock

Preferred stock acquisition date 11/25/2024 Date Series B Preferred Stock of the issuer was acquired

Date of notice 08/19/2026 Date the Rule 144 sale notice was signed and dated

Key Terms

Rule 144, Series B Preferred Stock, conversion, affiliate

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Series B Preferred Stock financial

"Acquired upon conversion of Series B Preferred Stock of the Issuer"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

conversion financial

"Acquired upon conversion of Series B Preferred Stock of the Issuer"

Conversion is the exchange of one type of financial instrument for another, most commonly turning convertible bonds or preferred shares into common stock. It matters to investors because conversion changes the number of outstanding shares and ownership stakes—like trading a coupon for a slice of a company—potentially reducing each existing owner's portion, affecting per-share earnings, voting power and the market value of the stock.

affiliate regulatory

"Affiliate 144: Securities Information"

FAQ

What is being sold under Rule 144 for MANE in this notice?

The notice covers a proposed sale of 690,601 shares of Veradermics, Inc. common stock under Rule 144 by Averill Master Fund, Ltd., with BofA Securities, Inc. acting as the broker on the NYSE.

Who is the selling security holder for MANE in this Rule 144 filing?

The selling security holder is Averill Master Fund, Ltd., identified as an affiliate. The shares to be sold are Veradermics, Inc. common stock that Averill holds after converting Series B Preferred Stock acquired from the issuer.

How many MANE shares are covered by this Rule 144 sale?

The notice covers 690,601 shares of Veradermics, Inc. common stock. These shares were acquired upon conversion of Series B Preferred Stock and are proposed to be sold through BofA Securities, Inc. on the NYSE.

When were the MANE shares proposed for sale acquired and converted?

The Series B Preferred Stock was acquired on November 25, 2024 and was converted into Veradermics, Inc. common stock on February 5, 2026, creating the 690,601 common shares covered by this Rule 144 notice.

Does this MANE Rule 144 notice show prior sales in the last three months?

No. The section for securities sold during the past 3 months does not list any transactions, indicating no reported Rule 144 sales by this seller in that period in this notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 07:14 PM Accepted by SEC EDGAR 08/19/2026 - 07:14 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001939329
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Veradermics, Inc.
SEC File Number	001-43097
Address of Issuer	470 James St. New Haven CONNECTICUT 06513
Phone	(228) 372 3376
Name of Person for Whose Account the Securities are To Be Sold	Averill Master Fund, Ltd.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	BofA Securities, Inc. One Bryant Park 8th Floor New York NY 10036	690601	74066957.25	41780136	08/19/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/05/2026	Acquired upon conversion of Series B Preferred Stock of the Issuer, which Series B Preferred Stock was acquired on November 25, 2024	Issuer			690601	02/05/2026	Conversion of Series B Preferred Stock

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	N/A
Date of Notice	08/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Andrew Nathanson
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)